Impact of the COVID-19 Pandemic on Healthcare Workers' Risk of Infection and Outcomes in a Large, Integrated Health System.


Journal

Journal of general internal medicine
ISSN: 1525-1497
Titre abrégé: J Gen Intern Med
Pays: United States
ID NLM: 8605834

Informations de publication

Date de publication:
11 2020
Historique:
received: 01 08 2020
accepted: 17 08 2020
pubmed: 3 9 2020
medline: 1 1 2021
entrez: 3 9 2020
Statut: ppublish

Résumé

Understanding the impact of the COVID-19 pandemic on healthcare workers (HCW) is crucial. Utilizing a health system COVID-19 research registry, we assessed HCW risk for COVID-19 infection, hospitalization, and intensive care unit (ICU) admission. Retrospective cohort study with overlap propensity score weighting. Individuals tested for SARS-CoV-2 infection in a large academic healthcare system (N = 72,909) from March 8-June 9, 2020, stratified by HCW and patient-facing status. SARS-CoV-2 test result, hospitalization, and ICU admission for COVID-19 infection. Of 72,909 individuals tested, 9.0% (551) of 6145 HCW tested positive for SARS-CoV-2 compared to 6.5% (4353) of 66,764 non-HCW. The HCW were younger than the non-HCW (median age 39.7 vs. 57.5, p < 0.001) with more females (proportion of males 21.5 vs. 44.9%, p < 0.001), higher reporting of COVID-19 exposure (72 vs. 17%, p < 0.001), and fewer comorbidities. However, the overlap propensity score weighted proportions were 8.9 vs. 7.7 for HCW vs. non-HCW having a positive test with weighted odds ratio (OR) 1.17, 95% confidence interval (CI) 0.99-1.38. Among those testing positive, weighted proportions for hospitalization were 7.4 vs. 15.9 for HCW vs. non-HCW with OR of 0.42 (CI 0.26-0.66) and for ICU admission: 2.2 vs. 4.5 for HCW vs. non-HCW with OR of 0.48 (CI 0.20-1.04). Those HCW identified as patient facing compared to not had increased odds of a positive SARS-CoV-2 test (OR 1.60, CI 1.08-2.39, proportions 8.6 vs. 5.5), but no statistically significant increase in hospitalization (OR 0.88, CI 0.20-3.66, proportions 10.2 vs. 11.4) and ICU admission (OR 0.34, CI 0.01-3.97, proportions 1.8 vs. 5.2). In a large healthcare system, HCW had similar odds for testing SARS-CoV-2 positive, but lower odds of hospitalization compared to non-HCW. Patient-facing HCW had higher odds of a positive test. These results are key to understanding HCW risk mitigation during the COVID-19 pandemic.

Sections du résumé

BACKGROUND
Understanding the impact of the COVID-19 pandemic on healthcare workers (HCW) is crucial.
OBJECTIVE
Utilizing a health system COVID-19 research registry, we assessed HCW risk for COVID-19 infection, hospitalization, and intensive care unit (ICU) admission.
DESIGN
Retrospective cohort study with overlap propensity score weighting.
PARTICIPANTS
Individuals tested for SARS-CoV-2 infection in a large academic healthcare system (N = 72,909) from March 8-June 9, 2020, stratified by HCW and patient-facing status.
MAIN MEASURES
SARS-CoV-2 test result, hospitalization, and ICU admission for COVID-19 infection.
KEY RESULTS
Of 72,909 individuals tested, 9.0% (551) of 6145 HCW tested positive for SARS-CoV-2 compared to 6.5% (4353) of 66,764 non-HCW. The HCW were younger than the non-HCW (median age 39.7 vs. 57.5, p < 0.001) with more females (proportion of males 21.5 vs. 44.9%, p < 0.001), higher reporting of COVID-19 exposure (72 vs. 17%, p < 0.001), and fewer comorbidities. However, the overlap propensity score weighted proportions were 8.9 vs. 7.7 for HCW vs. non-HCW having a positive test with weighted odds ratio (OR) 1.17, 95% confidence interval (CI) 0.99-1.38. Among those testing positive, weighted proportions for hospitalization were 7.4 vs. 15.9 for HCW vs. non-HCW with OR of 0.42 (CI 0.26-0.66) and for ICU admission: 2.2 vs. 4.5 for HCW vs. non-HCW with OR of 0.48 (CI 0.20-1.04). Those HCW identified as patient facing compared to not had increased odds of a positive SARS-CoV-2 test (OR 1.60, CI 1.08-2.39, proportions 8.6 vs. 5.5), but no statistically significant increase in hospitalization (OR 0.88, CI 0.20-3.66, proportions 10.2 vs. 11.4) and ICU admission (OR 0.34, CI 0.01-3.97, proportions 1.8 vs. 5.2).
CONCLUSIONS
In a large healthcare system, HCW had similar odds for testing SARS-CoV-2 positive, but lower odds of hospitalization compared to non-HCW. Patient-facing HCW had higher odds of a positive test. These results are key to understanding HCW risk mitigation during the COVID-19 pandemic.

Identifiants

pubmed: 32875500
doi: 10.1007/s11606-020-06171-9
pii: 10.1007/s11606-020-06171-9
pmc: PMC7462108
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3293-3301

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS097719
Pays : United States
Organisme : NIDDK NIH HHS
ID : U54 DK083912
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002548
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK114425
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK066143
Pays : United States
Organisme : AHRQ HHS
ID : K08 HS024128
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL125177
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL111314
Pays : United States
Organisme : NHLBI NIH HHS
ID : UG3 HL140144
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK110988
Pays : United States

Commentaires et corrections

Type : UpdateOf

Références

JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):729-732
pubmed: 32614442
J Hosp Infect. 2020 Apr 14;:
pubmed: 32302722
Ann Intern Med. 2020 Sep 1;173(5):W86
pubmed: 32687391
J Infect. 2020 Jul;81(1):147-178
pubmed: 32277966
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):477-481
pubmed: 32298247
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1075-1076
pubmed: 32456720
Cell Discov. 2020 Mar 16;6:14
pubmed: 32194980
Ann Transl Med. 2018 Feb;6(3):42
pubmed: 29610734
JAMA Cardiol. 2020 Sep 1;5(9):988-990
pubmed: 32936260
Am J Epidemiol. 2019 Jan 1;188(1):250-257
pubmed: 30189042
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1118-1119
pubmed: 32307028
JAMA. 2020 Aug 18;324(7):703-704
pubmed: 32663246
Lancet. 2020 May 2;395(10234):e77-e78
pubmed: 32333843
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):472-476
pubmed: 32298249
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347200
Clin Infect Dis. 2021 Feb 16;72(4):682-685
pubmed: 32562541
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Ann Intern Med. 2020 Sep 1;173(5):410-412
pubmed: 32343764
Chest. 2020 Oct;158(4):1364-1375
pubmed: 32533957
Infect Control Hosp Epidemiol. 2020 Nov;41(11):1321-1322
pubmed: 32616090

Auteurs

Anita D Misra-Hebert (AD)

Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA. misraa@ccf.org.
Healthcare Delivery and Implementation Science Center, Cleveland Clinic, Cleveland, OH, USA. misraa@ccf.org.
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. misraa@ccf.org.

Lara Jehi (L)

Department of Neurology, Cleveland Clinic, Cleveland, OH, USA.
Information Technology Division Administration, Cleveland Clinic, Cleveland, OH, USA.

Xinge Ji (X)

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.

Amy S Nowacki (AS)

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.

Steven Gordon (S)

Department of Infectious Disease, Cleveland Clinic, Cleveland, OH, USA.

Paul Terpeluk (P)

Department of Occupational Health, Cleveland Clinic, Cleveland, OH, USA.

Mina K Chung (MK)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.

Reena Mehra (R)

Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, USA.

Katherine M Dell (KM)

Center for Pediatric Nephrology, Cleveland Clinic Children's Hospital, Cleveland, OH, USA.

Nathan Pennell (N)

Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.

Aaron Hamilton (A)

Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA.

Alex Milinovich (A)

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.

Michael W Kattan (MW)

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.

James B Young (JB)

Healthcare Delivery and Implementation Science Center, Cleveland Clinic, Cleveland, OH, USA.
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH